Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia
| Autor: | Mindaugas Stoškus, Jurgita Sejoniene, Laimonas Griskevicius, Vilma Valceckiene, Regina Pileckyte, Mindaugas Jurgutis, Egle Gineikiene, Tadas Zvirblis, Andrius Degulys |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Chronic lymphocytic leukemia High dose methylprednisolone Gastroenterology Methylprednisolone Drug Administration Schedule Antibodies Monoclonal Murine-Derived Refractory Risk Factors Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Prospective Studies Aged Chromosome Aberrations Dose-Response Relationship Drug business.industry Hematology Middle Aged medicine.disease Prognosis Leukemia Lymphocytic Chronic B-Cell Survival Analysis Surgery Fludarabine Blood Cell Count Treatment Outcome Oncology Drug Resistance Neoplasm Hyperglycemia Toxicity Mutation Rituximab Female Neoplasm Recurrence Local Tumor Suppressor Protein p53 Trisomy business medicine.drug Follow-Up Studies |
| Zdroj: | Leukemialymphoma. 52(6) |
| ISSN: | 1029-2403 |
| Popis: | This study evaluated the efficacy and safety of dose-dense high-dose methylprednisolone (HDMP) plus rituximab (Rtx) in patients with high-risk CLL. Twenty-nine patients with relapsed or progressive CLL with adverse cytogenetics (17p deletion, TP53 mutation, 11q deletion, and/or trisomy 12) and/or progression within 12 months of fludarabine treatment were included. HDMP (1 g/m(2)) was administered daily for 5 days of each treatment course. Rtx was administered on days 1 (375 mg/m(2)) and 5 (500 mg/m(2)) of the first treatment course, on days 1 (500 mg/m(2)) and 5 (500 mg/m(2)) of the second course, and on day 1 (500 mg/m(2)) of courses 3-6. The cycles were repeated every 21 days. The overall response rate (ORR) was 62%, and 28% of patients had stable disease. In 13 patients with 17p deletion/TP53 mutation, ORR was 69%. After 22 months, the median progression-free and overall survivals were 12 and 31 months, respectively. The most frequent toxicity was hyperglycemia, and three deaths occurred in the study. Dose-dense treatment with HDMP and Rtx is an effective therapy with a favorable safety profile in patients with high-risk CLL, including those with 17p deletion/TP53 mutation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |